RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment
RareCyte®, a leader in precision biology products and technologies, today announced a significant expansion of its spatial proteomics portfolio with the commercial launch of the Orion™ HT and Orion™ LE systems, alongside the appointment of Neil Kennedy as President. These advancements position the company to accelerate adoption of spatial proteomics in clinical and translational research.
